Stiff person syndrome and other immune-mediated movement disorders - New insights

Current Opinion in Neurology

Volumn 29, Issue 4, 2016, Pages 496-506

  Balint, Bettina ^a,b   Bhatia, Kailash P ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

Author keywords

movement disorders; neuronal antibodies; stiff person syndrome

Indexed keywords

4 AMINOBUTYRIC ACID A RECEPTOR ANTIBODY; AMPHIPHYSIN; AMPHIPHYSIN ANTIBODY; DIPEPTIDYL PEPTIDASE LIKE PROTEIN 6 ANTIBODY; GAMMA AMINOBUTYRIC ACID TYPE A RECEPTOR ASSOCIATED PROTEIN ANTIBODY; GEPHYRIN ANTIBODY; GLUTAMATE DECARBOXYLASE ANTIBODY; GLYCINE RECEPTOR ANTIBODY; GLYCINE TRANSPORTER 2 ANTIBODY; PROTEIN ANTIBODY; UNCLASSIFIED DRUG;

AICARDI GOUTIERES SYNDROME; ANTIBODY TITER; ANTIPHOSPHOLIPID SYNDROME; ATAXIA; AUTOIMMUNITY; BEHCET DISEASE; BRAIN DISEASE; CELIAC DISEASE; CEREBELLAR ATAXIA; CHOREA; CHOREA MINOR; CHRONIC LYMPHOCYTIC INFLAMMATION WITH PONTINE PERIVASCULAR ENHANCEMENT RESPONSIVE TO STEROID; ENDOCYTOSIS; EXOCYTOSIS; GENETICS; HASHIMOTO ENCEPHALOPATHY; HERPES SIMPLEX ENCEPHALITIS; HUMAN; IMMUNOPATHOLOGY; MOTOR DYSFUNCTION; MYOCLONUS; NERVE CELL EXCITABILITY; NERVE CELL PLASTICITY; NERVE DEGENERATION; NEUROTRANSMISSION; NONHUMAN; OPSOCLONUS MYOCLONUS SYNDROME; PARKINSONISM; REVIEW; SJOEGREN SYNDROME; STEROID RESPONSIVE ENCEPHALOPATHY; STEROID RESPONSIVE ENCEPHALOPATHY WITH THYROID ANTIBODY; STIFF LIMB SYNDROME; STIFF MAN SYNDROME; SYNAPTIC TRANSMISSION; SYSTEMIC LUPUS ERYTHEMATOSUS; TAUOPATHY; DEGENERATIVE DISEASE; IMMUNOLOGY; NERVE CELL; NERVOUS SYSTEM MALFORMATION; NEUROLOGIC DISEASE; PATHOPHYSIOLOGY;

AUTOIMMUNE DISEASES OF THE NERVOUS SYSTEM; AUTOIMMUNITY; HUMANS; NERVOUS SYSTEM MALFORMATIONS; NEURODEGENERATIVE DISEASES; NEURONS; STIFF-PERSON SYNDROME; TAUOPATHIES;

EID: 84973299849     PISSN: 13507540     EISSN: 14736551     Source Type: Journal    
DOI: 10.1097/WCO.0000000000000351     Document Type: Review

References (83)

1. Vincent A, Bien CG, Irani SR, Waters P. Autoantibodies associated with diseases of the CNS: new developments and future challenges. Lancet Neurol 2011; 10:759-772.
2. Lancaster E, Dalmau J. Neuronal autoantigens-pathogenesis, associated disorders and antibody testing. Nat Rev Neurol 2012; 8:380-390.
3. Meinck HM, Thompson PD. Stiff man syndrome and related conditions. Mov Disord 2002; 17:853-866.
4. Khasani S, Becker K, Meinck HM. Hyperekplexia and stiff-man syndrome: abnormal brainstem reflexes suggest a physiological relationship. J Neurol Neurosurg Psychiatry 2004; 75:1265-1269.
5. Butler MH, Hayashi A, Ohkoshi N, et al. Autoimmunity to gephyrin in stiff-man syndrome. Neuron 2000; 26:307-312.
6. De Camilli P, Thomas A, Cofiell R, et al. The synaptic vesicle-associated protein amphiphysin is the 128-kD autoantigen of stiff-man syndrome with breast cancer. J Exp Med 1993; 178:2219-2223.
7. Solimena M, Folli F, Denis-Donini S, et al. Autoantibodies to glutamic acid decarboxylase in a patient with stiff-man syndrome, epilepsy, and type I diabetes mellitus. N Engl J Med 1988; 318:1012-1020.
8. Raju R, Rakocevic G, Chen Z, et al. Autoimmunity to GABAA-receptorassociated protein in stiff-person syndrome. Brain 2006; 129:3270-3276.
9. Hutchinson M, Waters P, McHugh J, et al. Progressive encephalomyelitis, rigidity, and myoclonus: a novel glycine receptor antibody. Neurology 2008; 71:1291-1292.
10. Balint B, Blöcker IM, Unger M, et al. Antibody spectrum in stiff person syndrome and related disorders. Mov Disord 2015; 30:263.
11. Balint B, Jarius S, Nagel S, et al. Progressive encephalomyelitis with rigidity and myoclonus: a new variant with DPPX antibodies. Neurology 2014; 82:1521-1528.
12. Murinson BB, Guarnaccia JB. Stiff-person syndrome with amphiphysin antibodies: distinctive features of a rare disease. Neurology 2008; 71:1955-1958.
13. Geis C, Weishaupt A, Hallermann S, et al. Stiff person syndrome-associated autoantibodies to amphiphysin mediate reduced GABAergic inhibition. Brain 2010; 133:3166-3180.
14. Sommer C, Weishaupt A, Brinkhoff J, et al. Paraneoplastic stiff-person syndrome: passive transfer to rats by means of IgG antibodies to amphiphysin. Lancet 2005; 365:1406-1411.
15. Werner C, Pauli M, Doose S, et al. Human autoantibodies to amphiphysin induce defective presynaptic vesicle dynamics and composition. Brain 2016; 139:365-379.
16. Cunningham ME, McGonigal R, Meehan GR, et al. Anti-ganglioside antibodies are removed from circulation in mice by neuronal endocytosis. Brain 2016. [Epub ahead of print]
17. Wessig C, Klein R, Schneider MF, et al. Neuropathology and binding studies in anti-amphiphysin-associated stiff-person syndrome. Neurology 2003; 61:195-198.
18. Burton AR, Baquet Z, Eisenbarth GS, et al. Central nervous system destruction mediated by glutamic acid decarboxylase-specific CD4 T cells. J Immunol 2010; 184:4863-4870.
19. Petit-Pedrol M, Armangue T, Peng X, et al. Encephalitis with refractory seizures, status epilepticus, and antibodies to the GABAA receptor: a case series, characterisation of the antigen, and analysis of the effects of antibodies. Lancet Neurol 2014; 13:276-286.
20. Chang T, Alexopoulos H, McMenamin M, et al. Neuronal surface and glutamic acid decarboxylase autoantibodies in nonparaneoplastic stiff person syndrome. JAMA Neurol 2013; 70:1140-1149.
21. Gresa-Arribas N, Arino H, Martinez-Hernandez E, et al. Antibodies to inhibitory synaptic proteins in neurological syndromes associated with glutamic acid decarboxylase autoimmunity. PLoS One 2015; 10:e0121364.
22. Geis C, Weishaupt A, Grunewald B, et al. Human stiff-person syndrome IgG induces anxious behavior in rats. PLoS One 2011; 6:e16775.
23. Hansen N, Grunewald B, Weishaupt A, et al. Human stiff person syndrome IgG-containing high-titer anti-GAD65 autoantibodies induce motor dysfunction in rats. Exp Neurol 2013; 239:202-209.
24. Fouka P, Alexopoulos H, Akrivou S, et al. GAD65 epitope mapping and search for novel autoantibodies in GAD-associated neurological disorders. J Neuroimmunol 2015; 281:73-77.
25. Arino H, Gresa-Arribas N, Blanco Y, et al. Cerebellar ataxia and glutamic acid decarboxylase antibodies: immunologic profile and long-term effect of immunotherapy. JAMA Neurol 2014; 71:1009-1016.
26. Rakocevic G, Hussain A. Stiff person syndrome improvement with chemotherapy in a patient with cutaneous T cell lymphoma. Muscle Nerve 2013; 47:938-939.
27. Hagiwara H, Enomoto-Nakatani S, Sakai K, et al. Stiff-person syndrome associated with invasive thymoma: a case report. J Neurol Sci 2001; 193:59-62.
28. Sinnreich M, Assal F, Hefft S, et al. Anti-GAD antibodies and breast cancer in a patient with stiff-person syndrome: a puzzling association. Eur Neurol 2001; 46:51-52.
29. Silverman IE. Paraneoplastic stiff limb syndrome. J Neurol Neurosurg Psychiatry 1999; 67:126-127.
30. McHugh JC, Murray B, Renganathan R, et al. GAD antibody positive paraneoplastic stiff person syndrome in a patient with renal cell carcinoma. Mov Disord 2007; 22:1343-1346.
31. Balint B, Bhatia KP. Isolated and combined dystonia syndromes-an update on new genes and their phenotypes. Eur J Neurol 2015; 22:610-617.
32. Zhou C, Huang Z, Ding L, et al. Altered cortical GABAA receptor composition, physiology, and endocytosis in a mouse model of a human genetic absence epilepsy syndrome. J Biol Chem 2013; 288:21458-21472.
33. Urak L, Feucht M, Fathi N, et al. A GABRB3 promoter haplotype associated with childhood absence epilepsy impairs transcriptional activity. Hum Mol Genet 2006; 15:2533-2541.
34. Alexopoulos H, Akrivou S, Dalakas MC. Glycine receptor antibodies in stiffperson syndrome and other GAD-positive CNS disorders. Neurology 2013; 81:1962-1964.
35. McKeon A, Martinez-Hernandez E, Lancaster E, et al. Glycine receptor autoimmune spectrum with stiff-man syndrome phenotype. JAMA Neurol 2013; 70:44-50.
36. Carvajal-Gonzalez A, Leite MI, Waters P, et al. Glycine receptor antibodies in PERM and related syndromes: characteristics, clinical features and outcomes. Brain 2014; 137:2178-2192.
37. Martinez-Hernandez E, Arino H, McKeon A, et al. Clinical and immunologic investigations in patients with stiff-person spectrum disorder. JAMA Neurol 2016. [Epub ahead of print]
38. Clerinx K, Breban T, Schrooten M, et al. Progressive encephalomyelitis with rigidity and myoclonus: resolution after thymectomy. Neurology 2011; 76:303-304.
39. Kyskan R, Chapman K, Mattman A, Sin D. Antiglycine receptor antibody and encephalomyelitis with rigidity and myoclonus (PERM) related to small cell lung cancer. BMJ Case Rep 2013; 2013; bcr2013010027.
40. De Blauwe SN, Santens P, Vanopdenbosch LJ. Anti-glycine receptor antibody mediated progressive encephalomyelitis with rigidity and myoclonus associated with breast cancer. Case Rep Neurol Med 2013; 2013:589154.
41. McKeon A, Robinson MT, McEvoy KM, et al. Stiff-man syndrome and variants: clinical course, treatments, and outcomes. Arch Neurol 2012; 69:230-238.
42. Derksen A, Stettner M, Stocker W, Seitz RJ. Antiglycine receptor-related stiff limb syndrome in a patient with chronic lymphocytic leukaemia. BMJ Case Rep 2013; 2013; bcr2013008667.
43. Carta E, Chung SK, James VM, et al. Mutations in the GlyT2 gene (SLC6A5) are a second major cause of startle disease. J Biol Chem 2012; 287:28975-28985.
44. Tobin WO, Lennon VA, Komorowski L, et al. DPPX potassium channel antibody: frequency, clinical accompaniments, and outcomes in 20 patients. Neurology 2014; 83:1797-1803.
45. Stokin GB, Popovic M, Gelpi E, et al. Neuropathologic features of antidipeptidyl-peptidase-like protein-6 antibody encephalitis. Neurology 2015; 84:430-432.
46. Boronat A, Gelfand JM, Gresa-Arribas N, et al. Encephalitis and antibodies to dipeptidyl-peptidase-like protein-6, a subunit of Kv4. 2 potassium channels. Ann Neurol 2013; 73:120-128.
47. Stoeck K, Carstens PO, Jarius S, et al. Prednisolone and azathioprine are effective in DPPX antibody-positive autoimmune encephalitis. Neurol Neuroimmunol Neuroinflamm 2015; 2:e86.
48. Nadal MS, Ozaita A, Amarillo Y, et al. The CD26-related dipeptidyl aminopeptidase-like protein DPPX is a critical component of neuronal A-type K channels. Neuron 2003; 37:449-461.
49. Piepgras J, Holtje M, Michel K, et al. Anti-DPPX encephalitis: pathogenic effects of antibodies on gut and brain neurons. Neurology 2015; 85:890-897.
50. Niwa N, Nerbonne JM. Molecular determinants of cardiac transient outward potassium current (I(to)) expression and regulation. J Mol Cell Cardiol 2010; 48:12-25.
51. Sun W, Maffie JK, Lin L, et al. DPP6 establishes the A-type K() current gradient critical for the regulation of dendritic excitability in CA1 hippocampal neurons. Neuron 2011; 71:1102-1115.
52. Ramdhani RA, Frucht SJ. Isolated chorea associated with LGI1 antibody. Tremor Other Hyperkinet Mov (N Y) 2014; 4; tre-04-213-4821-1.
53. Vynogradova I, Savitski V, Heckmann JG. Hemichorea associated with CASPR2 antibody. Tremor Other Hyperkinet Mov (N Y) 2014; 4:239.
54. Tofaris GK, Irani SR, Cheeran BJ, et al. Immunotherapy-responsive chorea as the presenting feature of LGI1-antibody encephalitis. Neurology 2012; 79:195-196.
55. O'Toole O, Lennon VA, Ahlskog JE, et al. Autoimmune chorea in adults. Neurology 2013; 80:1133-1144.
56. Armangue T, Titulaer MJ, Malaga I, et al. Pediatric anti-N-methyl-D-aspartate receptor encephalitis-clinical analysis and novel findings in a series of 20 patients. J Pediatr 2013; 162:850-856.
57. Hacohen Y, Deiva K, Pettingill P, et al. N-methyl-D-aspartate receptor antibodies in post-herpes simplex virus encephalitis neurological relapse. Mov Disord 2014; 29:90-96.
58. Mohammad SS, Sinclair K, Pillai S, et al. Herpes simplex encephalitis relapse with chorea is associated with autoantibodies to N-methyl-D-aspartate receptor or dopamine-2 receptor. Mov Disord 2014; 29:117-122.
59. Wickstrom R, Fowler A, Cooray G, et al. Viral triggering of anti-NMDA receptor encephalitis in a child-an important cause for disease relapse. Eur J Paediatr Neurol 2014; 18:543-546.
60. Desena A, Graves D, Warnack W, Greenberg BM. Herpes simplex encephalitis as a potential cause of anti-N-methyl-D-aspartate receptor antibody encephalitis: report of 2 cases. JAMA Neurol 2014; 71:344-346.
61. Scharf M, Miske R, Heidenreich F, et al. Neuronal Na/K ATPase is an autoantibody target in paraneoplastic neurologic syndrome. Neurology 2015; 84:1673-1679.
62. Lopez-Chiriboga AS, Komorowski L, Kumpfel T, et al. Metabotropic glutamate receptor type 1 autoimmunity: clinical features and treatment outcomes. Neurology 2016; 86:1009-1013.
63. Jarius S, Martinez-Garcia P, Hernandez AL, et al. Two new cases of anti-Ca (anti-ARHGAP26/GRAF) autoantibody-associated cerebellar ataxia. J Neuroinflamm 2013; 10:7.
64. Jarius S, Scharf M, Begemann N, et al. Antibodies to the inositol 1, 4, 5-trisphosphate receptor type 1 (ITPR1) in cerebellar ataxia. J Neuroinflamm 2014; 11:206.
65. Doss S, Numann A, Ziegler A, et al. Anti-Ca/anti-ARHGAP26 antibodies associated with cerebellar atrophy and cognitive decline. J Neuroimmunol 2014; 267:102-104.
66. Sweadner KJ, Toro C, Whitlow CT, et al. ATP1A3 mutation in adult rapidonset ataxia. PLoS One 2016; 11:e0151429.
67. Balint B, Bhatia KP. Dystonia: an update on phenomenology, classification, pathogenesis and treatment. Curr Opin Neurol 2014; 27:468-476.
68. Armangue T, Sabater L, Torres-Vega E, et al. Clinical and immunological features of opsoclonus-myoclonus syndrome in the era of neuronal cell surface antibodies. JAMA Neurol 2016; 73:417-424.
69. Panzer JA, Anand R, Dalmau J, Lynch DR. Antibodies to dendritic neuronal surface antigens in opsoclonus myoclonus ataxia syndrome. J Neuroimmunol 2015; 286:86-92.
70. Klaas JP, Ahlskog JE, Pittock SJ, et al. Adult-onset opsoclonus-myoclonus syndrome. Arch Neurol 2012; 69:1598-1607.
71. Armangue T, Titulaer MJ, Sabater L, et al. A novel treatment-responsive encephalitis with frequent opsoclonus and teratoma. Ann Neurol 2014; 75:435-441.
72. McKeon A, Lennon VA, Pittock SJ, et al. The neurologic significance of celiac disease biomarkers. Neurology 2014; 83:1789-1796.
73. Hacohen Y, Dlamini N, Hedderly T, et al. N-methyl-D-aspartate receptor antibody-associated movement disorder without encephalopathy. Dev Med Child Neurol 2014; 56:190-193.
74. Udani V, Desai N, Botre A. Partial manifestation of anti-NMDA-R encephalitis with predominant movement disorder. Mov Disord Clin Pract 2016; 3:80-82.
75. Ha AD, Parratt JD, Babu S, et al. Movement disorders associated with CLIPPERS. Mov Disord 2014; 29:148-150.
76. Pittock SJ, Debruyne J, Krecke KN, et al. Chronic lymphocytic inflammation with pontine perivascular enhancement responsive to steroids (CLIPPERS). Brain 2010; 133:2626-2634.
77. Sabater L, Gaig C, Gelpi E, et al. A novel non-rapid-eye movement and rapideye-movement parasomnia with sleep breathing disorder associated with antibodies to IgLON5: a case series, characterisation of the antigen, and postmortem study. Lancet Neurol 2014; 13:575-586.
78. Hogl B, Heidbreder A, Santamaria J, et al. IgLON5 autoimmunity and abnormal behaviours during sleep. Lancet (London, England) 2015; 385:1590.
79. Simabukuro MM, Sabater L, Adoni T, et al. Sleep disorder, chorea, and dementia associated with IgLON5 antibodies. Neurol Neuroimmunol Neuroinflamm 2015; 2:e136.
80. Brüggemann N, Wandinger KP, Gaig C, et al. Dystonia, lower limb stiffness, and upward gaze palsy in a patient with IgLON5 antibodies. Mov Disord 2016; 31:762-764.
81. Crow YJ, Manel N. Aicardi-Goutiè res syndrome and the type I interferonopathies. Nat Rev Immunol 2015; 15:429-440.
82. Hacohen Y, Zuberi S, Vincent A, et al. Neuromyelitis optica in a child with Aicardi-Goutiè res syndrome. Neurology 2015; 85:381-383.
83. Livingston JH, Lin JP, Dale RC, et al. A type I interferon signature identifies bilateral striatal necrosis due to mutations in ADAR1. J Med Genet 2014; 51:76-82.